CY1121474T1 - Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv - Google Patents

Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv

Info

Publication number
CY1121474T1
CY1121474T1 CY20171101278T CY171101278T CY1121474T1 CY 1121474 T1 CY1121474 T1 CY 1121474T1 CY 20171101278 T CY20171101278 T CY 20171101278T CY 171101278 T CY171101278 T CY 171101278T CY 1121474 T1 CY1121474 T1 CY 1121474T1
Authority
CY
Cyprus
Prior art keywords
treatment
ribabirin
combination
immediate action
hcv patients
Prior art date
Application number
CY20171101278T
Other languages
English (en)
Inventor
Barry M. Bernstein
Sandeep Dutta
Wei Liu
Thomas J. PODSADECKI
Andrew L. Campbell
Rajeev M. Menon
Chih-Wei Lin
Tianli WANG
Walid M. Awni
Sven MENSING
Original Assignee
Abbvie Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121474(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc. filed Critical Abbvie Inc.
Publication of CY1121474T1 publication Critical patent/CY1121474T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση ασχολείται με θεραπείες άνευ ιντερφερόνης για τη θεραπευτική αγωγή HCV. Κατά προτίμηση, η θεραπευτική αγωγή είναι μέσα σε μια βραχύτερη διάρκεια θεραπευτικής αγωγής, όπως όχι παραπάνω από 12 εβδομάδες. Σε μια άποψη, η θεραπευτική αγωγή περιλαμβάνει χορήγηση τουλάχιστον δυο αντιϊκών παραγόντων άμεσης δράσης και ριμπαβιρίνης σε ένα υποκείμενο με λοίμωξη HCV, όπου η θεραπευτική αγωγή διαρκεί για 12 εβδομάδες και δεν περιλαμβάνει χορήγηση ιντερφερόνης, και οι εν λόγω τουλάχιστον δυο αντιϊικοί παράγοντες άμεσης δράσης περιλαμβάνουν (α) Ένωση 1 και (β) Ένωση 2 ή ένα φαρμακευτικώς αποδεκτό άλας αυτών όπως αποκαλύπτεται στην περιγραφή.
CY20171101278T 2013-03-14 2017-12-06 Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv CY1121474T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361783437P 2013-03-14 2013-03-14
PCT/US2014/027556 WO2014152635A1 (en) 2013-03-14 2014-03-14 Combination of direct acting antiviral agents and ribavirin for treating hcv patients

Publications (1)

Publication Number Publication Date
CY1121474T1 true CY1121474T1 (el) 2020-05-29

Family

ID=50771575

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171101278T CY1121474T1 (el) 2013-03-14 2017-12-06 Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv

Country Status (27)

Country Link
US (1) US20140274934A1 (el)
EP (4) EP3915559A1 (el)
JP (3) JP6563894B2 (el)
KR (2) KR20180045055A (el)
CN (3) CN109908353A (el)
AU (3) AU2014239322B2 (el)
BR (1) BR112015020918A2 (el)
CA (1) CA2901818C (el)
CY (1) CY1121474T1 (el)
DK (1) DK2968302T3 (el)
EA (2) EA201890507A1 (el)
ES (1) ES2654109T3 (el)
HK (2) HK1213191A1 (el)
HR (1) HRP20171898T1 (el)
HU (1) HUE036069T2 (el)
IL (2) IL240445B (el)
LT (1) LT2968302T (el)
MX (1) MX2015012536A (el)
NO (1) NO3090119T3 (el)
PL (1) PL2968302T3 (el)
PT (1) PT2968302T (el)
RS (1) RS56735B1 (el)
SG (2) SG11201507361YA (el)
SI (1) SI2968302T1 (el)
TW (2) TW202002979A (el)
WO (1) WO2014152635A1 (el)
ZA (1) ZA201705080B (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106456621A (zh) * 2013-03-14 2017-02-22 艾伯维公司 用于治疗hcv的方法
SI2968302T1 (en) * 2013-03-14 2018-04-30 Abb Vie Inc. Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
MX2016005393A (es) * 2013-10-25 2016-08-11 Abbvie Inc Metodos para tratar vhc.
US20150174194A1 (en) * 2013-12-19 2015-06-25 Abbvie Inc. Methods for treating liver transplant recipients
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
ES2825373T3 (es) 2016-01-08 2021-05-17 Entrust Datacard Corp Mecanismo de impresión de tarjetas con trayectoria de retorno de tarjetas
WO2017189978A1 (en) 2016-04-28 2017-11-02 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CA3037719A1 (en) * 2016-09-23 2018-03-29 Abbvie Inc. Dose adjustment
CA2994496A1 (en) * 2017-02-14 2018-08-14 Abbvie Inc. Methods for treating hcv
CA2981993A1 (en) * 2017-08-02 2019-02-02 Abbvie Inc. Methods for treating hcv
CN108329332A (zh) * 2018-03-16 2018-07-27 安徽华昌高科药业有限公司 一种制备Glecaprevir的方法
EP3773753A4 (en) * 2018-04-10 2021-12-22 ATEA Pharmaceuticals, Inc. TREATMENT OF PATIENTS INFECTED WITH THE HEPATITIS C VIRUS WITH CIRRHOSIS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010013522A (es) * 2008-06-10 2011-05-03 Janssen Pharmaceutica Nv Uso de telaprevir en combinacion con interferon pegilado y ribavirina para tratar el virus de la hepatitis c.
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DK2455376T3 (en) * 2009-06-11 2015-03-02 Abbvie Bahamas Ltd Heterocyclic compounds as inhibitors of hepatitis C virus (HCV)
NZ608720A (en) 2010-09-21 2015-03-27 Enanta Pharm Inc Macrocyclic proline derived hcv serine protease inhibitors
AR088463A1 (es) 2011-10-21 2014-06-11 Abbvie Inc Metodos para el tratamiento de hcv
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
SI2968302T1 (en) 2013-03-14 2018-04-30 Abb Vie Inc. Combination of directly-acting antiviral agents and ribavarin for the treatment of patients with HCV

Also Published As

Publication number Publication date
IL267927A (en) 2019-09-26
IL240445A0 (en) 2015-09-24
HK1213191A1 (zh) 2016-06-30
HRP20171898T1 (hr) 2018-04-06
JP2016513703A (ja) 2016-05-16
EP3733180A1 (en) 2020-11-04
WO2014152635A9 (en) 2014-12-11
PL2968302T4 (pl) 2018-04-30
CN108187056A (zh) 2018-06-22
AU2014239322A1 (en) 2015-08-27
IL240445B (en) 2019-07-31
AU2018202581A1 (en) 2018-05-10
RS56735B1 (sr) 2018-03-30
SI2968302T1 (en) 2018-04-30
TW201505633A (zh) 2015-02-16
AU2020201656A1 (en) 2020-03-26
MX2015012536A (es) 2016-01-12
NO3090119T3 (el) 2018-03-31
HUE036069T2 (hu) 2018-06-28
TW202002979A (zh) 2020-01-16
DK2968302T3 (en) 2017-12-18
KR101853605B1 (ko) 2018-05-03
US20140274934A1 (en) 2014-09-18
EP3915559A1 (en) 2021-12-01
EP3318258B1 (en) 2020-05-13
SG11201507361YA (en) 2015-10-29
JP2019214585A (ja) 2019-12-19
AU2018202581B2 (en) 2019-12-05
EA030482B1 (ru) 2018-08-31
AU2014239322B2 (en) 2018-04-05
CN109908353A (zh) 2019-06-21
BR112015020918A2 (pt) 2017-07-18
PT2968302T (pt) 2018-01-03
TWI678205B (zh) 2019-12-01
JP2019167347A (ja) 2019-10-03
EA201591701A1 (ru) 2016-02-29
EA201890507A1 (ru) 2018-07-31
WO2014152635A1 (en) 2014-09-25
EP2968302B1 (en) 2017-09-06
HK1255257A1 (zh) 2019-08-09
SG10201709840UA (en) 2018-01-30
PL2968302T3 (pl) 2018-04-30
ZA201705080B (en) 2019-02-27
EP3318258A1 (en) 2018-05-09
EP2968302A1 (en) 2016-01-20
CN105007921B (zh) 2018-12-11
CN105007921A (zh) 2015-10-28
JP6563894B2 (ja) 2019-08-21
EP2968302B9 (en) 2019-02-13
LT2968302T (lt) 2017-12-27
ES2654109T3 (es) 2018-02-12
KR20180045055A (ko) 2018-05-03
KR20150129035A (ko) 2015-11-18
CA2901818C (en) 2021-05-04
CA2901818A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CY1121474T1 (el) Συνδυασμος αντιϊικων παραγοντων αμεσης δρασης και ριμπαβιρινης για την θεραπευτικη αγωγη ασθενων me hcv
CY1119025T1 (el) Συνδυασμος δυο αντιιικων για την αγωγη της ηπατιτιδας c
CY1124742T1 (el) 4'-φθορο-νουκλεοσιδια, 4'-φθορο-νουκλοεοτιδια και αναλογα αυτων για τη θεραπευτικη αγωγη toy hcv
CY1121735T1 (el) 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
UY37998A (es) Agentes antivirales contra la hepatitis b
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
CY1123570T1 (el) Τροποποιητες πυρηνικης πρωτεϊνης ηπατιτιδας β
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CO2021008055A2 (es) Heterociclos funcionalizados como agentes antivirales
CO2018009382A2 (es) Eliminación del virus de la hepatitis b con agentes antivirales
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
CY1117584T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, cx3cr1
EA201490254A1 (ru) Комбинированное лечение гепатита с
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
CY1124220T1 (el) Θεραπεια της λοιμωξης του ιου της ηπατιτιδας δελτα με ιντερφερονη λαμδα
CY1117504T1 (el) Παραγωγα 1-βενζυλ-3-υδροξυμεθυλινδαζολης και η χρηση τους στη θεραπευτικη αντιμετωπιση νοσων που βασιζονται στην εκφραση των mcp-1, και cx3cr1
CY1114089T1 (el) Μακροχρονια θεραπεια της μολυνσης απο hiv με tcm278
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2018000240A (es) Metodos para tratar el vhc.
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου